CELG News Alert Celgene Corp (CELG) 113.52 01/03/2015 13:32:

New Post Public Reply Private Reply Replies (0) Message Board

Jan 3, 2015 at 2:32 PM

Celgene Corp (CELG) 113.52 $CELG

How These 3 Stocks Doubled Investors' Money in Q4
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 03, 9:31AM CST
Source: Flickr user Tax Credits Most of the time, life-changing financial gains are generated over the long haul, not in the blink of an eye. However, sometimes stocks can put up jaw-dropping returns over a short period of time too. For example,...
BLUE: 91.26 (-0.46), ISIS: 61.57 (-0.17), ALNY: 97.77 (+0.77), OVAS: 45.83 (+1.61), GILD: 94.91 (+0.65), RGLS: 17.19 (+1.15), CELG: 113.52 (+1.66)

Final Glance: Biotechnology companies
AP - Fri Jan 02, 5:52PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
GILD: 94.91 (+0.65), AMGN: 159.89 (+0.60), CELG: 113.52 (+1.66)

Cellectis Is Late To The CAR-T Cell Race, But Could Finish First
Intrepid Investor - at Seeking Alpha - Fri Jan 02, 3:21PM CST

BLUE: 91.26 (-0.46), BLCM: 22.86 (-0.18), KITE: 60.61 (+2.94), JUNO: 48.25 (-3.97), GSK: 42.37 (-0.37), NVS: 92.25 (-0.41), CELG: 113.52 (+1.66)

An Investor's Guide: Market-Leading Industries In 2014
at Investor's Business Daily - Fri Jan 02, 1:57PM CST
At this time a year ago, the world was gearing up for the Winter Olympics in Sochi, Russia. Few things put in perspective the contrast experienced by global markets in 2014 like the vast squandering of political capital that followed the Sochi Games...
SPLS: 17.61 (-0.51), PTRY: 36.60 (-0.46), MNK: 96.96 (-2.07), BIIB: 342.01 (+2.56), ACT: 259.13 (+1.72), EA: 46.87 (-0.14), HA: 25.27 (-0.78), PANW: 121.42 (-1.15), LUV: 42.69 (+0.37), CELG: 113.52 (+1.66), AGN: 212.75 (+0.16), TTWO: 28.09 (+0.06), VDSI: 27.30 (-0.91), VA: 43.81 (+0.56), AAL: 53.91 (+0.28), ODP: 8.43 (-0.14)

Midday Glance: Biotechnology companies
AP - Fri Jan 02, 12:20PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 94.91 (+0.65), AMGN: 159.89 (+0.60), CELG: 113.52 (+1.66)

Stocks Reverse Lower; Apple Plunges Below Support
at Investor's Business Daily - Fri Jan 02, 10:59AM CST
Stocks were lower midday Friday after turning tail in the first session of 2015. The Nasdaq fell 0.7%, the S&P 500 lost 0.3% and the Dow Jones industrial average slipped 0.1%. Volume was tracking well above Wednesday's levels in the stock market...
BIIB: 342.01 (+2.56), ACT: 259.13 (+1.72), IBM: 162.06 (+1.62), ALXN: 186.60 (+1.57), MSFT: 46.76 (+0.31), LOCK: 15.89 (-2.62), AAPL: 109.33 (-1.05), CELG: 113.52 (+1.66)

Individual Investor Portfolio: Solid Results, But Energy Sell-Off And Biotechnology Add Volatility
James Sands - at Seeking Alpha - Fri Jan 02, 9:45AM CST

KMI: 42.81 (+0.50), BIIB: 342.01 (+2.56), ANET: 62.68 (+1.92), PCYC: 124.46 (+2.20), MKC: 73.95 (-0.35), HSY: 103.71 (-0.22), JBHT: 83.21 (-1.04), SFM: 34.02 (+0.04), GWW: 255.22 (+0.33), GOOG: 524.81 (-1.59), PCP: 238.44 (-2.44), SNI: 75.94 (+0.67), UPS: 110.38 (-0.79), PEP: 94.44 (-0.12), T: 33.87 (+0.28), CMI: 146.42 (+2.25), AAPL: 109.33 (-1.05), UNP: 118.61 (-0.52), PSX: 72.29 (+0.59), NSC: 109.15 (-0.46), FB: 78.45 (+0.43), VFC: 73.76 (-1.14), DISCA: 34.48 (+0.03), COP: 68.92 (-0.14), WFC: 54.70 (-0.12), TSN: 39.95 (-0.14), CELG: 113.52 (+1.66), WWAV: 34.76 (-0.23), PXD: 149.89 (+1.04), GILD: 94.91 (+0.65), PG: 90.44 (-0.65)

Early Glance: Biotechnology companies
AP - Fri Jan 02, 9:21AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 94.91 (+0.65), AMGN: 159.89 (+0.60), CELG: 113.52 (+1.66)

Celgene (CELG) Breaks Through Resistance at $113.94
Comtex SmarTrend(R) - Fri Jan 02, 8:58AM CST
Celgene (NASDAQ:CELG) has opened bullishly above the pivot of $112.73 today and has reached the first level of resistance at $113.94. Investors may be interested in a cross of the next upside pivot targets of $116.03 and $119.33.
CELG: 113.52 (+1.66)

5 Biotech Stocks With Big News Due In January
at Investor's Business Daily - Wed Dec 31, 12:15PM CST
The biotech industry is set to hit the ground running in 2015, with January alone bringing a passel of potentially stock-moving events by some of the biggest players. The second full week of the month will bring the annual JPMorgan Healthcare...
BIIB: 342.01 (+2.56), ESRX: 84.65 (-0.02), VRTX: 123.07 (+4.27), GILD: 94.91 (+0.65), ABBV: 65.89 (+0.45), BMY: 59.51 (+0.48), CELG: 113.52 (+1.66)

These 3 Biotechs Are Looking at a Happy New Year
Todd Campbell, The Motley Fool - Motley Fool - Wed Dec 31, 11:33AM CST
This healthcare edition of Industry Focus takes a look at three biotech stocks and why each company is positioned for a great performance in the coming year. If your portfolio could use some exposure to healthcare and biotechs, join the Fool's...
NFLX: 348.94 (+7.33), MDVN: 101.79 (+2.18), JNJ: 104.52 (-0.05), AMZN: 308.52 (-1.83), JPM: 62.49 (-0.09), GILD: 94.91 (+0.65), AGIO: 109.76 (-2.28), AAPL: 109.33 (-1.05), XLRN: 38.26 (-0.70), CELG: 113.52 (+1.66)

Jim Cramer's 'Mad Money' Recap: How to Become an Even Better Investor
at The Street - Tue Dec 30, 6:00PM CST
Cramer's first rule: Diversification is the only way to invest.
DUK: 84.05 (+0.51), SVU: 9.65 (-0.05), FB: 78.45 (+0.43), SKT: 37.45 (+0.49), ED: 66.34 (+0.33), FRT: 135.74 (+2.28), RSH: 0.39 (+0.02), PLKI: 55.72 (-0.55), CELG: 113.52 (+1.66), RAD: 7.63 (+0.11), T: 33.87 (+0.28), S: 4.24 (+0.09), CMG: 678.40 (-6.11), GLD: 114.08 (+0.50), GOOGL: 529.55 (-1.11), VZ: 46.96 (+0.18), AAPL: 109.33 (-1.05), REGN: 410.16 (-0.09)

Will Biotech Fire On All Cylinders In 2015?
Life Sciences Report - at Seeking Alpha - Tue Dec 30, 3:15PM CST
Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication. The biotech market enjoyed a stellar 2013 and withstood a solid check in early...
MDT: 71.88 (-0.32), PFE: 31.33 (+0.18), CLDX: 18.41 (+0.16), COV: 102.07 (-0.21), INCY: 73.76 (+0.65), NBS: 3.73 (-0.04), BMY: 59.51 (+0.48), OMER: 25.01 (+0.23), CELG: 113.52 (+1.66), ISIS: 61.57 (-0.17), GILD: 94.91 (+0.65), NVAX: 5.76 (-0.17), AZN: 70.40 (+0.02), CEMP: 22.89 (-0.62), FPRX: 27.71 (+0.71)

Start the New Year Off Right With the 3 Best Biotech Stocks
Motley Fool Staff - Motley Fool - Tue Dec 30, 6:43AM CST
Source: Flickr user dpotera . While many are popping champagne corks to welcome in the new year, we know that many fellow Fools (probably too many of us) will be wondering which companies could be the best bets for our portfolios in 2015. To help...
GILD: 94.91 (+0.65), ABBV: 65.89 (+0.45), CELG: 113.52 (+1.66)

DoctoRx Positions For 2015: I Have Cut Back On My Exposure To All Biotech Substantially
SA Editors - Seeking Alpha - Tue Dec 30, 6:05AM CST
Today we present the fifth piece in Seeking Alpha's Positioning for 2015 series. This year we have once again asked experts on a range of different asset classes and investing strategies to offer their vision for the coming year and beyond....
BIIB: 342.01 (+2.56), SPY: 205.43 (-0.11), PTLA: 28.51 (+0.19), PCYC: 124.46 (+2.20), GILD: 94.91 (+0.65), ACHN: 13.33 (+1.08), MRK: 57.19 (+0.40), EW: 127.72 (+0.34), IBB: 306.34 (+2.99), HQH: 31.87 (+0.38), REGN: 410.16 (-0.09), CELG: 113.52 (+1.66)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FutureVault's AI Agents: Transforming Financial Workflows

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

FJBio Boosts Antibody Discovery with Sapio AI

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...

Sean Trahan Joins Citrin Cooperman: New Tax Lead

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

K-Beauty Takes Front Stage at Target Beauty Studio

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

The Chemical Industry and EPA: A Broken System?

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Dr. Desi Bartlett Teams Up with Glo for Perimenopause Focus

Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...

Cracking the Code of America's Delivery Addiction

America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....